Accuray (NASDAQ:ARAY – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Saturday.
Accuray Stock Up 5.2 %
Accuray stock opened at $1.83 on Friday. The stock has a market capitalization of $188.18 million, a PE ratio of -36.60 and a beta of 1.46. Accuray has a 12 month low of $1.40 and a 12 month high of $2.95. The business has a 50 day simple moving average of $2.15 and a 200-day simple moving average of $2.00. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88.
Accuray (NASDAQ:ARAY – Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. On average, analysts anticipate that Accuray will post 0.01 EPS for the current fiscal year.
Hedge Funds Weigh In On Accuray
Accuray Company Profile
Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Read More
- Five stocks we like better than Accuray
- What is Forex and How Does it Work?
- How to Build the Ultimate Everything ETF Portfolio
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Investing In Preferred Stock vs. Common Stock
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.